title: Insulin degludec aspart: One-year real world experience.
abstract: BACKGROUND
  This retrospective analysis describes the use of insulin degludec aspart (IDegAsp) in India.
  
  
  METHODS
  All subjects who had received IDegAsp for 52 weeks at two endocrine centers were included in this study.
  
  
  RESULTS
  Forty-eight subjects (40 men), with mean age of 54.33 ± 9.63 years and mean duration of diabetes of 6.33 ± 2.96 years, started IDegAsp as insulin of initiation (16), as an intensification regime (4), as de-escalation from basal-bolus therapy (16), or as switch from premixed insulin (12). The dose of IDegAsp fell from 43.17 ± 21.18 U/day or 0.56 ± 0.23 U/kg to 37.75 ± 17.13U/day (0.51 ± 0.12 U/kg) at 24 weeks and 41.41 ± 15.33 U/day (0.56 ± 0.17 U/kg) at 52 weeks. Hemoglobin A1c (HbA1c), which was 9.52 ± 1.27% at the start of therapy, fell to 7.51 ± 0.46% at 26 weeks and to 7.48 ± 0.40% at 52 weeks. Fasting plasma glucose fell from 154.08 ± 33.30 mg% to 108.58 ± 22.26 mg% at 26 weeks and 102.17 ± 12.79 mg% at 52 weeks. Of the 48 subjects, 39 (81.25%) achieved a target of HbA1c <7.0% at both 26 and 52 weeks. No episode of hypoglycemia was reported in the 4 weeks preceding the analysis.
  
  
  CONCLUSIONS
  This communication highlights the efficacy, safety, and tolerability, while providing insight into the usage patterns of IDegAsp.
authors.affiliation: Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
authors.affiliation: Department of Endocrinology, Excel Hospitals, Guwahati, Assam, India.
authors.forename: Manash P
authors.initials: MP
authors.lastname: Baruah
keywords: Coformulation; India; degludec aspart; insulin; type 2 diabetes